Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer
In this video, Vandana Abramson, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, discusses the various strategies utilized in the treatment of metastatic breast cancer. Dr Abramson says that they are looking at new mutations within the subgroups, specificallyPI3 kinase mutations, as targets for estrogen receptor positive breast cancer. For HER-2 positive breast cancer there are many new therapies such as, ado-trastuzumab emtansine, pertuzumab, trastuzumab and more. "That's where I really think breast cancer is headed, said Dr Abramson. "We are figuring out how we can target specific subtypes in a better way."
This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.
The group, led by Koch Institute director Tyler Jacks, used CRISPR to generate mutant genes that were then packaged into enteroviruses that were used to infect target organs in mice. This is a much faster process than the traditional method that need crossing genetically-engineered mice.
The study, published in Cell Stem Cell, identified a microRNA-mediated inhibitory pathway that repressed expression of the speech and language gene FOXP2, promoting metastases of breast cancer cells to distant sites.